Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,145 | 3 | 61.8% |
| Consulting Fee | $8,930 | 3 | 32.2% |
| Travel and Lodging | $1,204 | 6 | 4.3% |
| Food and Beverage | $386.68 | 8 | 1.4% |
| Education | $63.20 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $27,508 | 15 | $0 (2020) |
| Shionogi Inc | $122.57 | 1 | $0 (2017) |
| The Medicines Company | $72.53 | 3 | $0 (2017) |
| Novo Nordisk Inc | $14.62 | 1 | $0 (2022) |
| Astellas Pharma Global Development | $10.59 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $14.62 | 1 | Novo Nordisk Inc ($14.62) |
| 2020 | $2,240 | 1 | Allergan, Inc. ($2,240) |
| 2019 | $10,085 | 11 | Allergan Inc. ($10,085) |
| 2018 | $5,600 | 1 | Allergan Inc. ($5,600) |
| 2017 | $9,789 | 7 | Allergan Inc. ($9,583) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: Diabetes | ||||||
| 03/24/2020 | Allergan, Inc. | DALVANCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2019 | Allergan Inc. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2019 | Allergan Inc. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $178.19 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2019 | Allergan Inc. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $172.57 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/25/2019 | Allergan Inc. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $365.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/25/2019 | Allergan Inc. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $264.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/25/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $124.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/25/2019 | Allergan Inc. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $112.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/25/2019 | Allergan Inc. | DALVANCE (Drug) | Travel and Lodging | In-kind items and services | $112.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/25/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $42.09 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/24/2019 | Allergan Inc. | AVYCAZ (Drug) | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/30/2019 | Allergan Inc. | DALVANCE (Drug) | Consulting Fee | Cash or cash equivalent | $840.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/22/2018 | Allergan Inc. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/24/2017 | Astellas Pharma Global Development | Cresemba (Drug) | Food and Beverage | In-kind items and services | $10.59 | General |
| Category: Infectious Diseases | ||||||
| 10/05/2017 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $122.57 | General |
| 08/30/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/24/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/24/2017 | The Medicines Company | ORBACTIV (Drug) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/02/2017 | Allergan Inc. | AVYCAZ (Drug) | Education | In-kind items and services | $63.20 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/21/2017 | Allergan Inc. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,520.00 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 382 | 1,017 | $376,750 | $110,608 |
| 2022 | 2 | 327 | 909 | $332,070 | $87,673 |
| 2021 | 3 | 326 | 1,034 | $355,500 | $101,729 |
| 2020 | 2 | 273 | 775 | $209,750 | $59,673 |
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 262 | 884 | $309,400 | $93,889 | 30.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 91 | 91 | $59,150 | $14,295 | 24.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 19 | $4,750 | $1,371 | 28.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 23 | $3,450 | $1,053 | 30.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 255 | 836 | $284,620 | $75,981 | 26.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 72 | 73 | $47,450 | $11,692 | 24.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 210 | 824 | $271,920 | $78,825 | 29.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 78 | 84 | $54,600 | $14,991 | 27.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 38 | 126 | $28,980 | $7,913 | 27.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 199 | 700 | $161,000 | $46,095 | 28.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 74 | 75 | $48,750 | $13,578 | 27.9% |
About Dr. Matthew Mccarthy, MD
Dr. Matthew Mccarthy, MD is a Hospitalist healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/23/2008. The National Provider Identifier (NPI) number assigned to this provider is 1174773519.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Mccarthy, MD has received a total of $27,729 in payments from pharmaceutical and medical device companies, with $14.62 received in 2022. These payments were reported across 21 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($17,145).
As a Medicare-enrolled provider, Mccarthy has provided services to 1,308 Medicare beneficiaries, totaling 3,735 services with total Medicare billing of $359,683. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Practice Information
- Specialty Hospitalist
- Other Specialties Internal Medicine, Internal Medicine
- Location New York, NY
- Active Since 09/23/2008
- Last Updated 12/19/2023
- Taxonomy Code 208M00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174773519
Products in Payments
- DALVANCE (Drug) $21,595
- AVYCAZ (Drug) $5,913
- ORBACTIV (Drug) $72.53
- Ozempic (Drug) $14.62
- Cresemba (Drug) $10.59
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospitalist Doctors in New York
Dr. Tamim Nazif, M.d, M.D
Hospitalist — Payments: $159,851
Miss. Kiran Thakur, Md, MD
Hospitalist — Payments: $60,289
Nikhil Cordeiro, Md, MD
Hospitalist — Payments: $28,423
Dr. Bishoy Faltas, Md, MD
Hospitalist — Payments: $26,135
Douglas Tremblay, M.d, M.D
Hospitalist — Payments: $21,307
Dr. Partha Sardar, Md, MD
Hospitalist — Payments: $7,435